The results of our studies provide novel insights into pharmacological modulation of mutant CFTR function in native human CF epithelia and identified co-activation of the basolateral K+ channel KCNN4 as a potential strategy to augment therapeutic effects of CFTR potentiator and corrector drugs. This evidence concerns the gene KCNN4 and cystic fibrosis.